Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Daratumumab in multiple myeloma

It is easy to be overwhelmed by hype in cancer research, with promising new discoveries often portrayed as so-called game changers.1 Most new treatments for cancer are far from being transformative, but daratumumab is possibly a rare exception. It targets CD38, an antigen that is uniformly expressed in myeloma cells.2 As the most anticipated new drug in multiple myeloma in more than a decade, daratumumab has all the features that are necessary to make a substantive difference in a devastating cancer, which—despite many advances—manages to outwit all available treatments over time: a novel mechanism of action, single-agent activity, non-cross resistance, and safety.